This spring, the University of Tennessee Research Foundation was honored to recognize UT innovators from across the state at UTRF’s annual Innovation Awards. For the first time in two years, UTRF staff and valued partners gathered in Knoxville and Memphis to celebrate the innovation coming from the university. At the events, hosted at UT Knoxville (read more)
UTHSC
UTRF Licensee Veru, Inc. Announces Positive Results of COVID-19 Therapy’s Phase 3 Clinical Study, Seeking Emergency Use Authorization from FDA
UT Research Foundation licensee Veru, Inc. announced on April 11, 2022, that their Phase 3 clinical trial of sabizabulin as an oral therapy for hospitalized severe COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and death showed the drug to be safe and effective. The trial was halted early due to the (read more)
UT pharmacy students developing device to individualize the smoking cessation process
Smoking is one of the most prominent causes of preventable disease each year in the United States. According to the 2020 National Survey on Drug Use and Health, 57.3 million people reported tobacco or nicotine vaping use in the past month. Meanwhile, a 2017 study of smokers from the Centers for Disease Control and Prevention (read more)